LOS ANGELES, April 13, 2005 (PRIMEZONE) -- SmallcapInsights.com, http://www.SmallcapInsights.com, the online source for exclusive commentary, research, interviews and other key investor information, has announced the availability of an exclusive audio interview with Dr. Dov Shimon, Chief Medical Officer and Director of MIV Therapeutics (OTCBB:MIVT), a developer of next-generation biocompatible coatings and drug delivery technologies.
In the audio interview, Dr. Shimon provides an overview of the two recently filed patents on a new class of multi-layer/multi-drug delivery systems that expand MIV Therapeutics' (MIVT) intellectual property portfolio.
"Put simply, the advanced multi-drug eluting technologies that MIVT is developing will offer the medical device world, as well as the pharmacological industry, a system to enable a new category of capabilities in implanted drug-eluting devices," said Dr. Shimon.
Dr. Shimon is the founder of SagaX Inc., a company recently acquired by MIVT, and is a renowned cardiac and thoracic surgeon. He has performed more than 8,000 open-heart operations and other thoracic operations and has more than 18 years of experience in animal and clinical testing of medical devices. Dr. Shimon has been working since 1999 with medical device companies in design and implementation of preclinical and clinical studies.
MIVT is commercializing a line of next-generation proprietary advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and other implantable medical devices. The Company's biocompatible coating technology is designed to significantly improve the performance of stents and medical devices, both through advanced drug-elution, as well as by eliminating inflammation and other complications that occur with previous generations of stents and implanted medical devices.
The streaming audio interview can be accessed at http://www.SmallcapInsights.com/si/mivt. Registration to listen to the interview is free.
About MIV Therapeutics
MIVT has secured the exclusive worldwide license from the University of British Columbia to use and sublicense three patents for proprietary HAp coating technologies, including their application for the development, manufacture and sale of coated stents and other implantable medical devices. The above patent applications represent inventions developed internally and wholly owned by MIV Therapeutics Inc.
MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and other implantable medical devices. MIVT's ultra-thin coating has been derived from a unique biocompatible material called hydroxyapatite (HAp) that demonstrated during in-vivo animal trials excellent safety and superior healing properties pursued by the medical science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications.
MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and received a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the additional development of hydroxyapatite as a drug eluting coating. MIVT's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction of metal stents. The Company has progressed to the next development stage, which is expected to finalize the drug-eluting research and development program. Recently MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council - Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the next development stage, which is expected to finalize the drug-eluting research and development program. For more information, please visit http://www.mivtherapeutics.com
To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html
To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm
About SmallcapInsights.com
SmallcapInsights.com provides exclusive commentary, research, interviews and other information about the smallcap investment marketplace. SmallcapInsights.com strives to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on SmallcapInsights.com include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis. It is located at http://www.SmallcapInsights.com.
Forward-Looking Statements
Statements made on SmallcapInsights.com may contain forward-looking statements made by senior management of the companies presented here that involve risks and uncertainties, such as statements about plans, objectives, expectations, assumptions or future events. These statements involve estimates, assumptions, known and unknown risks, uncertainties and performances, or achievements expressed or implied by the forward-looking statements. Actual future results and trends may differ materially from those made in -- or suggested by -- statements presented here due to a variety of factors. Consequently, you should not place undue reliance on any forward-looking statements made here. Many of these and other risks and uncertainties are discussed in greater detail in recent filings with the Securities Exchange Commission for the companies that are present by SmallcapInsights.com
Compensation and Other Disclosures
SmallcapInsights.com is a wholly-owned subsidiary of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations services to public companies. The companies presented by SmallcapInsights.com are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. Trilogy receives compensation from MIV Therapeutics of $10,000 per month through November 2005 and thereafter for so long as Trilogy is retained to provide investor relations services. Trilogy has non-transferable warrants from this company to purchase 2,720,000 shares of common stock for $0.26 per share and expiring in November 2007, provided that Trilogy may not exercise the warrants to the extent that following such exercise Trilogy would beneficially own 5% or more or the outstanding common stock of this company.